Diagnosis and treatment of Alzheimer´s and other neurodementing dseases
A-beta-autoantibodies were isolated from the serum of Alzheimer patients. The cDNA and amino acid sequences of the variable regions of the heavy and the light chains were determined and all possible pairings of the chains were expressed in mammalian cells.<br>
A number of these pairings were found to bind with higher affinity to A-beta dimers than to A-beta monomers. One of these was shown to possess biological activities potentially useful for the treatment of Alzheimer´s disease.<br> Consensus sequences were determined and used to prepare human anti-beta-amyloid antibodies useful for preventing or treating neurodementing diseases like Alzheimer´s. These human anti-beta-amyloid antibodies are suitable for detecting and measuring the progression of neurodementing disease and methods are provided for delaying the onset or progression of these diseases.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
